This article was originally published in The Rose Sheet
Innovation benefits stemming from the combination of Gillette and Procter & Gamble will come more quickly than with P&G's acquisitions of Clairol and Wella, Chairman and CEO AG Lafley states during a presentation at a Consumer Analyst Group of New York conference Feb. 24 in Scottsdale, Ariz. In response to questions from analysts regarding slower than anticipated hair color innovation sharing, Lafley notes the two earlier acquisitions faced unique challenges, including the lack of a full product pipeline at Clairol and integration obstacles with Wella due to "idiosyncracies" in German law. Gillette is an innovation-driven company with a full product pipeline, Lafley says. Initial innovation sharing opportunities include women's hair removal, men's grooming and powered products, he adds...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.